Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Margolis

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
American Journal of Hematology|February 12, 2024
Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trialMary Eapen, Jianqun Kou, Martin Andreansky, et al.
British Journal of Clinical Pharmacology|July 9, 2021
Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteersBeat M Jucker, Edward J Fuchs, Sarah Lee, et al.
Blood|August 10, 2010
Evidence of dysregulation of dendritic cells in primary HIV infectionRachel Lubong Sabado, Meagan O'Brien, Abhignya Subedi, et al.
Plos One|May 17, 2011
Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapyCynthia Gay, Oliver Dibben, Jeffrey A Anderson, et al.
Journal of Virology|March 16, 2022
Altered Response Pattern following AZD5582 Treatment of SIV-Infected, ART-Suppressed Rhesus Macaque InfantsKatherine M Bricker, Veronica Obregon-Perko, Brianna Williams, et al.
The Lancet. HIV|June 5, 2020
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialRaphael J Landovitz, Sue Li, Joseph J Eron, et al.
Blood Advances|May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Pharmacoepidemiology and Drug Safety|July 6, 2012
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studiesVincent Lo Re, Kevin Haynes, Eileen E Ming, et al.
Science Immunology|June 13, 2020
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsLakshmanane Premkumar, Bruno Segovia-Chumbez, Ramesh Jadi, et al.
Photomedicine and Laser Surgery|May 19, 2006
Clinical and experimental applications of NIR-LED photobiomodulationKristina D Desmet, David A Paz, Jesse J Corry, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
American Journal of Hematology|February 12, 2024
Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trialMary Eapen, Jianqun Kou, Martin Andreansky, et al.
British Journal of Clinical Pharmacology|July 9, 2021
Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteersBeat M Jucker, Edward J Fuchs, Sarah Lee, et al.
Blood|August 10, 2010
Evidence of dysregulation of dendritic cells in primary HIV infectionRachel Lubong Sabado, Meagan O'Brien, Abhignya Subedi, et al.
Plos One|May 17, 2011
Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapyCynthia Gay, Oliver Dibben, Jeffrey A Anderson, et al.
Journal of Virology|March 16, 2022
Altered Response Pattern following AZD5582 Treatment of SIV-Infected, ART-Suppressed Rhesus Macaque InfantsKatherine M Bricker, Veronica Obregon-Perko, Brianna Williams, et al.
The Lancet. HIV|June 5, 2020
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialRaphael J Landovitz, Sue Li, Joseph J Eron, et al.
Blood Advances|May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Pharmacoepidemiology and Drug Safety|July 6, 2012
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studiesVincent Lo Re, Kevin Haynes, Eileen E Ming, et al.
Science Immunology|June 13, 2020
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsLakshmanane Premkumar, Bruno Segovia-Chumbez, Ramesh Jadi, et al.
Photomedicine and Laser Surgery|May 19, 2006
Clinical and experimental applications of NIR-LED photobiomodulationKristina D Desmet, David A Paz, Jesse J Corry, et al.
Pageof 12